oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 25 and Orforglipron for Obesity: New Insights In the OASIS 4 phase

It is currently being investigated in phase 3 trials, and results from a phase 2 trial published in the New England Journal of Medicine are show great promise

Supports glutathione synthesis: Glutathione is a powerful antioxidant that helps to protect cells from damage

A pooled analysis published in the National Institutes of Health PMC archive found tirzepatide reduced body weight more than semaglutide across different study designs, and a journal review summarized by the American College of Cardiology reported significantly greater weight loss with tirzepatide

It plays a crucial role in maintaining cellular health by neutralizing harmful molecules known as free radicals